Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00662597 · ClinicalTrials.gov registry record · Phase 3
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,285
- Enrollment target
NCT00662597: Clinical Trial Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00662597 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 1,285 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00662597, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,285 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with advanced lung cancer.
Interventions
- DRUG Placebo
- DRUG Paclitaxel
- DRUG carboplatin
- DRUG ASA404
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,285 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Why NCT00662597 stopped before completion
NCT00662597 is an interventional study that assigns participants to a tested intervention. Its 1,285 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00662597 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00662597 about?
NCT00662597 is a clinical study titled "ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer". The purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with advanced lung cancer.
What is the current status of trial NCT00662597?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,285 participants. The study started on 2008-04. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00662597?
The interventions under investigation include: Placebo (DRUG), Paclitaxel (DRUG), carboplatin (DRUG), ASA404 (DRUG).
Who is sponsoring clinical trial NCT00662597?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00662597's enrollment target sits among peer trials
1,285 197th of 2000 higher than 1,804 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06626022 · 1,284 participants · Phase 3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
- NCT05595642 · 1,290 participants · Phase 3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia